Mode of Alloantibody-Mediated Blockade of Allo-Sensitization for Tumor Allograft Rejection

Hwa Lai, Yoshinori Hasegawa, Kenji Mizoguchi, Tomoaki Yoshida, Ken Ichi Isobe, Kaoru Shimokata, Kohei Kawashima, Izumi Nakashima

Research output: Contribution to journalArticle

Abstract

The mode of alloantibody -mediated inhibition of allo-sensitization for tumor allograftrejection was studied. Relatively small amounts of anti-H-2d alloantiserum administered shortly before or after injection of allogeneic spleen cells blocked the allo-sensitization for second-set tumor allograft rejection. In contrast, the alloantiserum injected shortly before inoculation of tumor barely enhanced the tumor growth. The passively administered alloantiserum inhibited the sensitization for allospecific cytotoxic T lymphocyte responses in in vitro. Further study revealed that the allo-sensitization could be blocked with antiserum specific against only one of the expressed H-2 antigens on stimulator cells. Correspondingly, H-2Dd-monospecific monoclonal antibody (IgG2a) was effective in inhibiting the sensitization with cells expressing multiple H-2 alloantigens. These results suggest that antibody-mediated inactivation of stimulator cells as a whole is an important mechanism of the allograft enhancement.

Original languageEnglish
Pages (from-to)33-43
Number of pages11
JournalImmunobiology
Volume179
Issue number1
DOIs
Publication statusPublished - 1989

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Hematology

Fingerprint Dive into the research topics of 'Mode of Alloantibody-Mediated Blockade of Allo-Sensitization for Tumor Allograft Rejection'. Together they form a unique fingerprint.

  • Cite this

    Lai, H., Hasegawa, Y., Mizoguchi, K., Yoshida, T., Isobe, K. I., Shimokata, K., Kawashima, K., & Nakashima, I. (1989). Mode of Alloantibody-Mediated Blockade of Allo-Sensitization for Tumor Allograft Rejection. Immunobiology, 179(1), 33-43. https://doi.org/10.1016/S0171-2985(89)80005-1